Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Follitropin Beta→

Follitropin Beta Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
150490-85-0
Molecular formula
C538H834N148O164S13
Molecular weight
~30000 g/mol
Drug class
Recombinant human follicle-stimulating hormone (FSH) gonadotropin
Mechanism of action
Activates FSH receptors on ovarian granulosa cells to stimulate follicular growth and development. In male fertility regimens, FSH receptor activation on Sertoli cells supports spermatogenesis when used with human chorionic gonadotropin.
Indications / reported uses
  • Controlled ovarian stimulation to develop multiple follicles in women undergoing assisted reproductive technology
  • Induction of ovulation in selected women with anovulatory infertility
  • Stimulation of spermatogenesis in selected men with hypogonadotropic hypogonadism when used with hCG; product-specific criteria apply

Sources: EMA EPAR — Puregon (follitropin beta) · US DailyMed — Follitropin beta · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Follitropin Beta Environmental Risk Assessment (ERA) (the Follitropin Beta ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.